TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04014257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV1601(CHC2014)
Description: a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
Study: NCT04227561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal nerve block
Description: Pudendal nerve block will be performed under general anesthesia and guided by neurostimulation.~The local anesthetic solution (chirocaine 2.5mg/ml) will be injected in the ischiorectal fossa with a needle (a BBraun Stimuplex Ultra 360 22G 50mm needle) connected to a neurostimulator (Stimuplex HNS 12 neurostimulator). The neurostimulator will be used to determine the localization of pudendal nerve and to identify the precise site of injection. The contraction of the anal sphincter or bulbocavernosus muscle occurs when the pudendal nerve is reached.~These procedure will be performed bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penile nerve block
Description: The local anesthetic solution (chirocaine 2.5mg/ml) will be injected under the fascia of Scarpa with a real-time ultrasound guidance.~These procedure will be performed bilaterally.
Study: NCT04076800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
Study: NCT03672006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alteplase (recombinant t-PA)
Description: Medication administered to dwell in central venous catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Medication administered to dwell in central venous catheter
Study: NCT02789566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine 30 mg taken after meal in the morning.
Study: NCT01978717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Patients received general anesthesia for surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Patients received general anesthesia for surgery
Study: NCT00275834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: zonisamide 400 mg, 200 mg, or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: zonisamide 400 mg, 200 mg, or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zonisamide
Description: zonisamide 400 mg, 200 mg, or placebo
Study: NCT02646501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Antiarrhythmic drug
Study: NCT01200628

Intervention type: BEHAVIORAL
Intervention: DEPITAC
Description: heteroevaluation scale by a nurse during hospitalization
Study: NCT02646501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug
Description: Antiarrhythmic drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous stellate ganglion block (PSGB)
Description: percutaneous stellate ganglion block (PSGB)
Study: NCT00626808

Intervention type: DRUG
Intervention: No Intervention
Description: There were no interventions. No subjects were enrolled in this retrospective database study.
Study: NCT03774030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: several virtual 3-D complex audio environments
Description: The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
Study: NCT01445197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: 200 IU/kg administered daily
Study: NCT03878901

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: high risk warm
Description: Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: moderate risk warm
Description: 30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: low risk warm
Description: 30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
Study: NCT02711878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Move Program
Description: Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Let's Flex Program
Description: Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Motivational Interviewing
Description: Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing
Description: Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
Study: NCT02538822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic imaging
Description: In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical testing
Description: In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
Study: NCT03855267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol 20 MG/ML
Description: Pump propofol to keep bispectral index within 40 # 60

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 20 mg/ml , etomidate 2 mg/ml
Description: Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 20 mg/ml , etomidate 2 mg/ml
Description: Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 20 mg/ml , etomidate 2 mg/ml
Description: Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
Study: NCT03878901

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: passive warming
Description: cotton blanket warming through operation
Study: NCT01996124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol Fumarate
Description: 150 mcg inhalation powder, hard capsules, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose, dry inhalation powder, hard capsules via breezhaler
Study: NCT03102060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo gluten free diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03076723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in shunt opening pressure
Description: An individually determined change in shunt opening pressure is compared to no change in opening pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulated change in shunt opening pressure
Description: The shunt opening pressure is reset to the same setting.
Study: NCT04291768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened antibiotic treatment
Description: Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic treatment
Description: Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
Study: NCT05082311

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study
Study: NCT00853138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy
Description: In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week.
Study: NCT03875664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Extended-release local anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - injection
Description: Injectable normal saline solution
Study: NCT01688115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video
Description: The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
Study: NCT02369419

Intervention type: OTHER
Intervention: Frailty
Description: CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
Study: NCT04751188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 MG Oral Tablet
Description: Bezafibrate one tablet every 12 hours for six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet every 12 hours for six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: At a dose of 13 to 15 mg per Kg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: At a dose of 13 to 15 mg per Kg per day.
Study: NCT00757822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
Study: NCT03473795

Intervention type: BEHAVIORAL
Intervention: Questionnaire forms
Description: The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.

Intervention type: OTHER
Intervention: Bio-specimen samples
Description: Samples can include tissue, blood, urine, saliva, hair and nail clipping.
Study: NCT02170181

Intervention type: RADIATION
Intervention: SBRT
Description: SBRT to Oligometastases

Intervention type: RADIATION
Intervention: SBRT
Description: SBRT to Oligometastases

Intervention type: RADIATION
Intervention: SBRT
Description: SBRT to Oligometastases

Intervention type: RADIATION
Intervention: SBRT
Description: SBRT to Oligometastases
Study: NCT05401188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hospitalization
Description: Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
Study: NCT02885376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentoxol
Description: Mouthrinse

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouthrinse
Study: NCT04430153

Intervention type: OTHER
Intervention: Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer
Description: Accelerometers on both patients' wrists will give insight into the daily life upper limb use.

Intervention type: OTHER
Intervention: Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer
Description: Accelerometers on both patients' wrists will give insight into the daily life upper limb use.

Intervention type: OTHER
Intervention: Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer
Description: Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
Study: NCT03514290

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-lever laser
Description: Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth bleaching
Description: Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tooth bleaching
Description: Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The laser tip was positioned similarly to experimental group but without light irradiation
Study: NCT04028557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Support Systems, Clinical
Description: Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support Systems, Clinical
Description: Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
Study: NCT01098474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™ HB+Hib
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™ HB+Hib
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™ HB+Hib
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar™
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar™
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: Oral, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Oral, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Oral, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate™
Description: Intramuscular, 3 doses
Study: NCT01408602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRC375
Description: MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRC375 150mg
Description: MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
Study: NCT03669835

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mare milk supplement
Description: Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard therapy
Description: For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
Study: NCT02855749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided percutaneous tracheostomy
Description: to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
Study: NCT00830492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: 100 mg from cycle day 3 through 7

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: cycle day 8
Study: NCT02699203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Description: Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
Study: NCT02619994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locally-used WHO-approved MDR-TB regimen in Korea
Study: NCT02898662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1419
Description: Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events